Elpiscience is dedicated to transforming cancer treatment by developing innovative immunotherapies that turn “cold” tumors “hot”. By unlocking differentiated biology, we aim to enhance crosstalk between innate and adaptive immunity, harnessing the full potential of the immune system to fight cancer.
Elpiscience’s translational platform integrates cutting-edge immunobiology, PK/PD analysis, and multi-omics data to optimize drug development for tumor immunotherapy and autoimmune diseases. Our in vitro pharmacodynamics, DMPK & toxicology, and biomarker platforms ensure mechanism-driven research, precise dose selection, and biomarker-driven therapies. Through a science-first, data-driven approach, we accelerate the development of safe and effective breakthrough treatments.
